Arcturus Therapeutics Holdings Inc. revenue
Arcturus Therapeutics Holdings Inc.'s revenue was $82.0m in fiscal 2025, down 46.1% on the year before. Since fiscal 2018 ($15.8m) it has grown at a compound 26.6% a year. Over the last twelve months it was $29.4m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Collaboration Revenue | $67.2M | 81.9% | ▼ 51.4% |
| Grant | $14.8M | 18.1% | ▲ 6.4% |
From Arcturus Therapeutics Holdings Inc.'s 10-K filed March 3, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. | $29.4m | -76.0% | -51.9% |
| Tonix Pharmaceuticals Holding Corp. | $29.1m | 196.0% | — |
| Monte Rosa Therapeutics, Inc. | $28.7m | -83.9% | — |
| Stoke Therapeutics, Inc. | $27.6m | -86.2% | 46.1% |
| Abeona Therapeutics Inc. | $25.5m | -87.7% | 212.0% |
| Crispr Therapeutics AG | $25.2m | -34.3% | -47.1% |
Compare with peers
- Tonix Pharmaceuticals Holding Corp. revenue
- Monte Rosa Therapeutics, Inc. revenue
- Stoke Therapeutics, Inc. revenue
- Abeona Therapeutics Inc. revenue
- Crispr Therapeutics AG revenue
Head to head: ARCT vs TNXPARCT vs GLUEARCT vs STOK
More: Biotechnology stocks compared, Health Care sector, rankings of US companies